159 related articles for article (PubMed ID: 37060953)
1. Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression.
Zavaliangos-Petropulu A; McClintock SM; Khalil J; Joshi SH; Taraku B; Al-Sharif NB; Espinoza RT; Narr KL
J Affect Disord; 2023 Jul; 333():161-171. PubMed ID: 37060953
[TBL] [Abstract][Full Text] [Related]
2. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
[TBL] [Abstract][Full Text] [Related]
3. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression.
Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
J Affect Disord; 2020 Dec; 277():470-477. PubMed ID: 32871534
[TBL] [Abstract][Full Text] [Related]
4. Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression.
Liu W; Zhou Y; Zheng W; Wang C; Zhan Y; Lan X; Zhang B; Li H; Chen L; Ning Y
J Affect Disord; 2019 Dec; 259():1-6. PubMed ID: 31430662
[TBL] [Abstract][Full Text] [Related]
5. Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review.
Dai D; Miller C; Valdivia V; Boyle B; Bolton P; Li S; Seiner S; Meisner R
BMC Psychiatry; 2022 Feb; 22(1):140. PubMed ID: 35193541
[TBL] [Abstract][Full Text] [Related]
6. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
7. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression.
Shiroma PR; Albott CS; Johns B; Thuras P; Wels J; Lim KO
Int J Neuropsychopharmacol; 2014 Nov; 17(11):1805-13. PubMed ID: 24963561
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions.
Phillips JL; Van Geel A; Burhunduli P; Vasudev D; Batten LA; Norris S; Talbot J; Ortiz A; Owoeye O; Blier P
Int J Neuropsychopharmacol; 2022 Dec; 25(12):992-1002. PubMed ID: 35931041
[TBL] [Abstract][Full Text] [Related]
9. Hippocampal subfield volumes in treatment resistant depression and serial ketamine treatment.
Zavaliangos-Petropulu A; McClintock SM; Joshi SH; Taraku B; Al-Sharif NB; Espinoza RT; Narr KL
Front Psychiatry; 2023; 14():1227879. PubMed ID: 37876623
[TBL] [Abstract][Full Text] [Related]
10. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861
[TBL] [Abstract][Full Text] [Related]
11. Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study.
Kang MJY; Vazquez GH
J Affect Disord; 2022 Dec; 318():331-337. PubMed ID: 36070831
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Fava M; Freeman MP; Flynn M; Judge H; Hoeppner BB; Cusin C; Ionescu DF; Mathew SJ; Chang LC; Iosifescu DV; Murrough J; Debattista C; Schatzberg AF; Trivedi MH; Jha MK; Sanacora G; Wilkinson ST; Papakostas GI
Mol Psychiatry; 2020 Jul; 25(7):1592-1603. PubMed ID: 30283029
[TBL] [Abstract][Full Text] [Related]
13. Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion.
Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
J Affect Disord; 2018 Dec; 241():1-7. PubMed ID: 30081380
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
Shiroma PR; Johns B; Kuskowski M; Wels J; Thuras P; Albott CS; Lim KO
J Affect Disord; 2014 Feb; 155():123-9. PubMed ID: 24268616
[TBL] [Abstract][Full Text] [Related]
15. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.
Diamond PR; Farmery AD; Atkinson S; Haldar J; Williams N; Cowen PJ; Geddes JR; McShane R
J Psychopharmacol; 2014 Jun; 28(6):536-44. PubMed ID: 24699062
[TBL] [Abstract][Full Text] [Related]
16. Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
J Affect Disord; 2019 Mar; 246():241-247. PubMed ID: 30590286
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression.
Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
Transl Psychiatry; 2020 Jun; 10(1):206. PubMed ID: 32591498
[TBL] [Abstract][Full Text] [Related]
18. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M
Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373
[TBL] [Abstract][Full Text] [Related]
19. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Murrough JW; Perez AM; Pillemer S; Stern J; Parides MK; aan het Rot M; Collins KA; Mathew SJ; Charney DS; Iosifescu DV
Biol Psychiatry; 2013 Aug; 74(4):250-6. PubMed ID: 22840761
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression.
Chen MH; Lin WC; Wu HJ; Bai YM; Li CT; Tsai SJ; Hong CJ; Tu PC; Cheng CM; Su TP
CNS Spectr; 2021 Aug; 26(4):362-367. PubMed ID: 32419678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
